Cargando…

Does the Anti‐Tau Strategy in Progressive Supranuclear Palsy Need to Be Reconsidered? No

Detalles Bibliográficos
Autor principal:	Höglinger, Günter U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Controversy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485628/ https://www.ncbi.nlm.nih.gov/pubmed/34631939 http://dx.doi.org/10.1002/mdc3.13326

Ejemplares similares

Distribution patterns of tau pathology in progressive supranuclear palsy
por: Kovacs, Gabor G., et al.
Publicado: (2020)

Inferring the sequence of brain volume changes in progressive supranuclear palsy using MRI
por: Franzmeier, Nicolai, et al.
Publicado: (2022)

Clinical Features Observed in General Practice Associated With the Subsequent Diagnosis of Progressive Supranuclear Palsy
por: Kwasny, Mary J., et al.
Publicado: (2021)

An autopsy-confirmed case of progressive supranuclear palsy with predominant postural instability
por: Kurz, Carolin, et al.
Publicado: (2016)

Validation of the Parkinson's Disease Caregiver Burden Questionnaire in Progressive Supranuclear Palsy
por: Klietz, Martin, et al.
Publicado: (2021)

Characterization of tau oligomeric seeds in progressive supranuclear palsy
por: Gerson, Julia E, et al.
Publicado: (2014)

SUMO1 Modification of Tau in Progressive Supranuclear Palsy
por: Takamura, Hironori, et al.
Publicado: (2022)

Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database
por: Viscidi, Emma, et al.
Publicado: (2021)

Latent trait modeling of tau neuropathology in progressive supranuclear palsy
por: Kouri, Naomi, et al.
Publicado: (2021)

Accurate digital quantification of tau pathology in progressive supranuclear palsy
por: Pansuwan, Tanrada, et al.
Publicado: (2023)

DescribePSP and ProPSP: German Multicenter Networks for Standardized Prospective Collection of Clinical Data, Imaging Data, and Biomaterials of Patients With Progressive Supranuclear Palsy
por: Respondek, Gesine, et al.
Publicado: (2021)

Clinical Conditions “Suggestive of Progressive Supranuclear Palsy”—Diagnostic Performance
por: Grimm, Max-Joseph, et al.
Publicado: (2020)

Feasibility of short imaging protocols for [(18)F]PI-2620 tau-PET in progressive supranuclear palsy
por: Song, Mengmeng, et al.
Publicado: (2021)

Tau burden and the functional connectome in Alzheimer’s disease and progressive supranuclear palsy
por: Cope, Thomas E, et al.
Publicado: (2018)

Longitudinal changes of early motor and cognitive symptoms in progressive supranuclear palsy: the OxQUIP study
por: Pereira, Marta F, et al.
Publicado: (2022)

Hospitalization Rates and Comorbidities in Patients with Progressive Supranuclear Palsy in Germany from 2010 to 2017
por: Zella, Maria Angela Samis, et al.
Publicado: (2020)

Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear Palsy
por: Simoes, Fabio A., et al.
Publicado: (2022)

Reduction in Volume of Nucleus Basalis of Meynert Is Specific to Parkinson’s Disease and Progressive Supranuclear Palsy but Not to Multiple System Atrophy
por: Rogozinski, Sophia, et al.
Publicado: (2022)

Does Topical Tretinoin Used for Chemoprevention Cause Increased Mortality?
por: Sangolli, Prabhakar M
Publicado: (2009)

Validation of mobile eye-tracking as novel and efficient means for differentiating progressive supranuclear palsy from Parkinson's disease
por: Marx, Svenja, et al.
Publicado: (2012)

Zolpidem in Progressive Supranuclear Palsy
por: Dash, Sandip K.
Publicado: (2013)

Genetics of Progressive Supranuclear Palsy
por: Im, Sun Young, et al.
Publicado: (2015)

Falls in Progressive Supranuclear Palsy
por: Brown, Fraser S., et al.
Publicado: (2019)

Exercise and Progressive Supranuclear Palsy: the need for explicit exercise reporting
por: Slade, Susan C., et al.
Publicado: (2019)

Molecular Processing of Tau Protein in Progressive Supranuclear Palsy: Neuronal and Glial Degeneration
por: Martínez-Maldonado, Alejandra, et al.
Publicado: (2021)

New PET technologies – embracing progress and pushing the limits
por: Aide, Nicolas, et al.
Publicado: (2021)

Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype
por: Jabbari, Edwin, et al.
Publicado: (2018)

Superiority of Formalin-Fixed Paraffin-Embedded Brain Tissue for in vitro Assessment of Progressive Supranuclear Palsy Tau Pathology With [(18)F]PI-2620
por: Willroider, Marie, et al.
Publicado: (2021)

Midbrain catecholaminergic neurons co-express α-synuclein and tau in progressive supranuclear palsy
por: Erro Aguirre, María Elena, et al.
Publicado: (2015)

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy
por: Smith, Ruben, et al.
Publicado: (2016)

Contribution of the astrocytic tau pathology to synapse loss in progressive supranuclear palsy and corticobasal degeneration
por: Briel, Nils, et al.
Publicado: (2020)

Progressive supranuclear palsy: diagnosis and management
por: Rowe, James B, et al.
Publicado: (2021)

Understanding fatigue in progressive supranuclear palsy
por: Ahn, Jong Hyeon, et al.
Publicado: (2021)

‘Hummingbird’ sign in progressive supranuclear palsy
por: Shukla, Rakesh, et al.
Publicado: (2009)

Clinical Approach to Progressive Supranuclear Palsy
por: Ling, Helen
Publicado: (2016)

Managing cognition in progressive supranuclear palsy
por: Rittman, Timothy, et al.
Publicado: (2016)

Hummingbird sign in progressive supranuclear palsy
por: Verma, Rajesh, et al.
Publicado: (2012)

Imaging in the diagnosis of progressive supranuclear palsy
por: Smith, Matthew D., et al.
Publicado: (2018)

Multireceptor fingerprints in progressive supranuclear palsy
por: Chiu, Wang Zheng, et al.
Publicado: (2017)

Frontrunner in Translation: Progressive Supranuclear Palsy
por: Shoeibi, Ali, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3v8ititkfbm2tli91v06k7bcq1